BIO unveils preliminary program for BIO Convention in China.August 10, 2012 -
During 2012 BIO Convention in China, Oct 24-25, executives from biotechnology, pharmaceutical companies, and investment firms in North America, Europe, and Asia will meet to explore business opportunities with China's emerging biotech sector. Preliminary program topics include globalization of Chinese companies; innovation in generics and biosimilars; comparative legal systems in U.S., Europe, and China; R/D trends in China; trends in cancer research; and regulatory review in China.
BIO Unveils Preliminary Program for the 2012 BIO Convention in China
Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
Press release date: August 7, 2012
Event to take place in Shanghai, China, October 24-25, 2012
BIO China 2012
WASHINGTON--The Biotechnology Industry Organization (BIO) announces the 2nd annual BIO Convention in China, a partnering and investor conference that will bring together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector. The event will take place October 24-25, 2012 in Shanghai, China.
"Through distinguished speakers, exemplary programming, compelling company presentations and exhibiting and networking opportunities, BIO China allows attendees to explore the vast business opportunities afforded by China's emerging biotech sector."
"As China positions itself as a major global player in the international biotechnology arena, it has included biotechnology as one of the seven strategic priorities for scientific and technological development in its 12th Five-year Plan," said Alan Eisenberg, Executive Vice President of Emerging Companies and Business Development at BIO. "Through distinguished speakers, exemplary programming, compelling company presentations and exhibiting and networking opportunities, BIO China allows attendees to explore the vast business opportunities afforded by China's emerging biotech sector."
Dr. Michael Rosenblatt, M.D., executive vice president and chief medical officer for Merck, will provide one of two keynote addresses on October 25th. Directly following Dr. Rosenblatt's keynote, Peng Wang, Ph.D., Chief Scientific Officer, Simcere will deliver his remarks. Governor Jon Huntsman, former U.S. Ambassador to China and Governor of Utah, will provide the third keynote address. Additional keynote speakers will be announced at a later date.
Panel sessions will highlight the latest issues and trends related to doing business in China. Preliminary program topics include the globalization of Chinese companies; innovation in generics and biosimilars; comparative legal systems in - U.S., Europe and China; R&D trends in China; trends in cancer research and regulatory review in China.
BIO and the BIO China Advisory Committee set the event agenda and program. Advisory Committee members include:
George Baeder, Partner, Monitor Group Asia
Xue Baizhong, Chairman & CEO, Nuokang Biopharma
Helen Chen, Director & Partner, L.E.K. Consulting
Lian Yong (Leon) Chen, Founder & Managing Partner, Frontline BioVentures
Li Chen, President & CEO, Hua Medicine, China
Bill Guo, Ph.D., Chairman & Founder, Venturepharm Group
May-Kin Ho, Ph.D., Advisory Director, Goldman, Sachs & Co.
James Li, Vice President & General Manager, Greater China, Amgen China
Aihua Pan, Ph.D., M.D., Chairman, SinoBioway Group
Rajesh Parekh, Director, Asia Pharmaceuticals & Medical Products Practice, McKinsey & Company
Yinxiang Wang, PhD, CEO & Chief Scientific Officer, Zhejiang Beta Pharma
Jerry Xiao, Vice General Manager, Corporate Technology Center, Fosun Pharma
Steve Yang, Vice President, Head of R&D, Asia and Emerging Markets, AstraZeneca, China
Tony Zhang, Vice President, Global External R&D, Asia, Eli Lilly and Company
Xu Zhang, Deputy President, Shanghai Branch, Chinese Academy of Sciences
BIO brings to China more than 15 years of experience in organizing international conferences for the biotech industry, including the BIO International Convention - the global event for biotechnology. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering(TM), an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors.
For more information on the BIO Convention in China, please visit here.
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling "innovations transforming our world." Subscribe to BIOtechNOW.
Biotechnology Industry Organization
Abigail Hirsch, 202-962-9235